Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.39 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.38 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.38 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.35 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.33 |
| ▸ | GPR119 | Q8TDV5 | 4/20 | 0.33 |
| ▸ | RET | P07949 | 1/20 | 0.32 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.32 |
| ▸ | CCNC | P24863 | 1/20 | 0.32 |
| ▸ | CDK8 | P49336 | 1/20 | 0.32 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.32 |
| ▸ | MET | P08581 | 1/20 | 0.32 |
| ▸ | JAK1 | P23458 | 1/20 | 0.32 |
| ▸ | JAK3 | P52333 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21473877 | 0.90 | DDB1 (0.49) | USP30DDB1CRBNIRAK4GPR119 | |
| SCHEMBL660078 | 0.87 | USP30 (0.49) | USP30DDB1CRBNNR1H2GPR119 | |
| SCHEMBL14205889 | 0.85 | JAK2 (0.32) | FFAR1JAK1JAK3 | |
| SCHEMBL9888308 | 0.82 | USP30 (0.38) | USP30DDB1CRBNNR1H2IRAK4 | |
| SCHEMBL23349424 | 0.82 | SCD (0.38) | USP30NR1H2FFAR1 | |
| SCHEMBL15273426 | 0.80 | USP30 (0.45) | USP30DDB1CRBNNR1H2GPR119 | |
| SCHEMBL25236223 | 0.80 | USP30 (0.45) | USP30DDB1CRBNNR1H2GPR119 | |
| SCHEMBL15273003 | 0.80 | USP30 (0.47) | USP30DDB1CRBNNR1H2GPR119 | |
| SCHEMBL2422527 | 0.80 | USP30 (0.55) | USP30DDB1CRBNGPR119FFAR1 | |
| SCHEMBL2423601 | 0.80 | USP30 (0.55) | USP30DDB1CRBNGPR119FFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10336722-B2 | Tetrahydroquinoline compositions as BET bromodomain inhibitors | FORMA THERAPEUTICS, INC. (US) | 2019-07-02 | — | — | US | disclosed |
| US-20180215766-A1 | TETRAHYDROQUINOLINE COMPOSITIONS AS BET BROMODOMAIN INHIBITORS | FORMA THERAPEUTICS, INC. | 2018-08-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180215766-A1 | TETRAHYDROQUINOLINE COMPOSITIONS AS BET BROMODOMAIN INHIBITORS | BRD4, BRD3, BRD1 | USP30 988/4885DDB1 704/4885CRBN 1276/4885 |
| US-10336722-B2 | Tetrahydroquinoline compositions as BET bromodomain inhibitors | BRD4, BRD3, BRD1 | USP30 988/4885DDB1 704/4885CRBN 1276/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.